mBio (Dec 2014)
Influenza Gain-of-Function Experiments: Their Role in Vaccine Virus Recommendation and Pandemic Preparedness
- S. Schultz-Cherry,
- R. J. Webby,
- R. G. Webster,
- A. Kelso,
- I. G. Barr,
- J. W. McCauley,
- R. S. Daniels,
- D. Wang,
- Y. Shu,
- E. Nobusawa,
- S. Itamura,
- M. Tashiro,
- Y. Harada,
- S. Watanabe,
- T. Odagiri,
- Z. Ye,
- G. Grohmann,
- R. Harvey,
- O. Engelhardt,
- D. Smith,
- K. Hamilton,
- F. Claes,
- G. Dauphin
Affiliations
- S. Schultz-Cherry
- WHO Collaborating Center for Studies on the Ecology of Influenza in Animals, Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
- R. J. Webby
- WHO Collaborating Center for Studies on the Ecology of Influenza in Animals, Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
- R. G. Webster
- WHO Collaborating Center for Studies on the Ecology of Influenza in Animals, Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
- A. Kelso
- WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- I. G. Barr
- WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- J. W. McCauley
- WHO Collaborating Centre for Reference and Research on Influenza, Division of Virology, MRC National Institute for Medical Research, Mill Hill, London, United Kingdom
- R. S. Daniels
- WHO Collaborating Centre for Reference and Research on Influenza, Division of Virology, MRC National Institute for Medical Research, Mill Hill, London, United Kingdom
- D. Wang
- WHO Collaborating Center for Reference and Research on Influenza, Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention China CDC, Beijing, People’s Republic of China
- Y. Shu
- WHO Collaborating Center for Reference and Research on Influenza, Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention China CDC, Beijing, People’s Republic of China
- E. Nobusawa
- WHO Collaborating Centre for Reference and Research on Influenza, National Institute of Infectious Diseases, Laboratory of Influenza Virus Surveillance, Influenza Virus Research Center, Tokyo, Japan
- S. Itamura
- WHO Collaborating Centre for Reference and Research on Influenza, National Institute of Infectious Diseases, Laboratory of Influenza Virus Surveillance, Influenza Virus Research Center, Tokyo, Japan
- M. Tashiro
- WHO Collaborating Centre for Reference and Research on Influenza, National Institute of Infectious Diseases, Laboratory of Influenza Virus Surveillance, Influenza Virus Research Center, Tokyo, Japan
- Y. Harada
- WHO Collaborating Centre for Reference and Research on Influenza, National Institute of Infectious Diseases, Laboratory of Influenza Virus Surveillance, Influenza Virus Research Center, Tokyo, Japan
- S. Watanabe
- WHO Collaborating Centre for Reference and Research on Influenza, National Institute of Infectious Diseases, Laboratory of Influenza Virus Surveillance, Influenza Virus Research Center, Tokyo, Japan
- T. Odagiri
- WHO Collaborating Centre for Reference and Research on Influenza, National Institute of Infectious Diseases, Laboratory of Influenza Virus Surveillance, Influenza Virus Research Center, Tokyo, Japan
- Z. Ye
- Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland, USA
- G. Grohmann
- Immunology and Vaccines, Therapeutic Goods Administration Laboratories, Woden, ACT, Australia
- R. Harvey
- National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom
- O. Engelhardt
- National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom
- D. Smith
- Center for Pathogen Evolution, Department of Zoology, WHO CC for Modeling Evolution and Control of Emerging Infectious Diseases, University of Cambridge, Cambridge, United Kingdom
- K. Hamilton
- OIE Scientific and Technical Department, OIE, Paris, France
- F. Claes
- OFFLU/EMPRES Laboratory Unit, Animal Health Service, FAO, Rome, Italy
- G. Dauphin
- OFFLU/EMPRES Laboratory Unit, Animal Health Service, FAO, Rome, Italy
- DOI
- https://doi.org/10.1128/mBio.02430-14
- Journal volume & issue
-
Vol. 5,
no. 6
Abstract
Abstract In recent years, controversy has arisen regarding the risks and benefits of certain types of gain-of-function (GOF) studies involving avian influenza viruses. In this article, we provide specific examples of how different types of data, including information garnered from GOF studies, have helped to shape the influenza vaccine production process—from selection of candidate vaccine viruses (CVVs) to the manufacture and stockpiling of safe, high-yield prepandemic vaccines for the global community. The article is not written to support a specific pro- or anti-GOF stance but rather to inform the scientific community about factors involved in vaccine virus selection and the preparation of prepandemic influenza vaccines and the impact that some GOF information has had on this process.
